The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Incivek™ (telaprevir) and Hepatitis C

What is Incivek™ (telaprevir)?

UPDATE: As of August 2014 Vertex announced it will discontinue selling Incivek.

On May 23, 2011, the U.S. Food and Drug Administration approved the prescription medication Incivek™ (telaprevir) for use in combination with peginterferon alfa and ribavirin to treat chronic Hepatitis C genotype 1 infection in adult patients who have not been treated before or who have failed previous treatment. The active ingredient in this 375 mg tablet is telaprevir.

Incivek™ is a Hepatitis C virus (HCV) NS3/4A protease inhibitor which works by binding to the virus and preventing it from multiplying.  It is to be used in combination with peginterferon and ribavirin. It is not to be used alone.

Last Updated: July 2014

Vertex Pharmaceuticals "Highlights of Prescribing Information - Incivek™" http://pi.vrtx.com/files/uspi_telaprevir.pdf. Retrieved May 23, 2011.

Vertex Pharmaceuticals "Medication Guide - Incivek™" http://pi.vrtx.com/files/usmedguide_telaprevir.pdf. Retrieved May 23, 2011.

Vertex Pharmaceuticals "For Patients - Helping People Get Incivek™ (telaprevir) tablets" http://www.vrtx.com/patients.html. Retrieved May 23, 2011.